Evaluating local recurrence of rectal cancer in Sweden
Official title: Local Recurrence Due to Rectal Cancer in Sweden - the Actual Incidence, Treatment and Outcome After Treatment
Run by Sahlgrenska University Hospital · NCT04404777 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study looks at how often rectal cancer comes back in patients in Sweden and tries to find out what factors might increase the chances of it returning, so doctors can provide better follow-up care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 12000 (estimated) |
| Sponsor | Sahlgrenska University Hospital Academic / other |
| Locations | 1 site (Gothenburg) |
| Trial ID | NCT04404777 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with rectal cancer who have undergone treatment with curative intent.
✕Probably not a fit
Patients with rectal cancer treated without curative intent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to validate the reporting of local recurrence of rectal cancer using a national registry. It will identify preoperative risk factors associated with local recurrence, which may indicate the need for more intensive follow-up care. The study will also assess treatment outcomes for patients who experienced local recurrence between 2007 and 2018, focusing on the role of multidisciplinary team conferences and surgical procedures in managing these cases.
Why it matters
Potential benefit: If successful, this study could lead to improved follow-up strategies and treatment outcomes for patients with rectal cancer.
How similar studies have gone: Other studies have shown success in validating registry data and identifying risk factors for cancer recurrence, making this approach promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Rectal cancer with a curative intent Exclusion Criteria: * Rectal cancer without curative intent
Where it's running
-
Dept. of Surgery, Sahlgrenska University Hospital/Ostra
Gothenburg, Sweden Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Characterization of the tumor microenvironment in locally advanced rectal cancer before and during neoadjuvant therapy
This observational study tests how the tumor and immune cells change in locally advanced rectal cancer from baseline to during neoadjuvant therapy using advanced genomic and immune profiling.
-
Neoadjuvant therapy for locally advanced low rectal cancer: adding fruquintinib to short-course radiotherapy with tislelizumab and CAPOX
This study tests whether adding fruquintinib to short-course radiotherapy plus tislelizumab and CAPOX before surgery helps people with locally advanced low rectal cancer achieve a better tumor response.
-
Gut and tumor bacteria patterns in metastatic versus non-metastatic colorectal cancer
This project will test whether bacteria in the gut and tumor differ between people whose colorectal cancer has spread and those whose cancer has not to see if bacterial signatures can help predict spread.
-
Comparing two surgical techniques for anal function after low rectal cancer surgery
This study is testing which of two surgical methods helps people with ultra-low rectal cancer have better bowel control and quality of life after surgery.
-
Comparing treatment options for mid-low rectal cancer
This study is testing different treatment options for mid-low rectal cancer to see which ones work best and are most cost-effective for patients and healthcare providers in China.
-
Platform program for evaluating treatments in metastatic HER2-positive breast cancer
This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.